Home › Compare › HIZOF vs ABBV
HIZOF yields 1.86% · ABBV yields 3.09%● Live data
📍 HIZOF pulled ahead of the other in Year 5
Combined, HIZOF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of HIZOF + ABBV for your $10,000?
Kanadevia Corp design, constructs, and manufactures energy-from-waste plants, desalination plants, and water and sewage treatment plants in Japan and internationally. It operates through three segments: Environment, Machinery & Infrastructure, and Other. The company builds various water-related facilities, including sludge recycling centers and desalination plants, and energy-related facilities, including biomass plants, as well as engages in wind power generation. It also provides marine diesel engines, deck machinery for ships, process equipment, filter presses, industrial equipment, steel stacks, and spent nuclear fuel casks, as well as various types of precision machinery for electronics, semiconductor, food, and medical-related sectors; and engineering, procurement, construction, and after-sales services. In addition, the company engages in building, monitoring, maintenance, and repair of bridges and hydraulic gates for dams and rivers; developing shield tunneling machines for the construction of underground motorways and subway tracks, maintenance and earthquake protection systems for steel structures, electric discharge impulse crushing system, GPS comprehensive oceanographic monitoring systems, GPS remote monitoring systems, and flap-gate type seawalls against flood disaster due to tsunamis or storm surges. Further, it offers all-solid-state lithium-ion batteries and Zeolite Membrane Elements. Hitachi Zosen Corporation was founded in 1881 and is headquartered in Osaka, Japan.
Full HIZOF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.